Actinium Financial Statements From 2010 to 2024

ATNM Stock  USD 7.94  0.18  2.22%   
Actinium Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Actinium Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Actinium Pharmaceuticals financial statements helps investors assess Actinium Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Actinium Pharmaceuticals' valuation are summarized below:
Gross Profit
M
Market Capitalization
220.4 M
Enterprise Value Revenue
1.1 K
Earnings Share
(1.93)
Quarterly Revenue Growth
(1.00)
There are over one hundred thirteen available fundamental signals for Actinium Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Actinium Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Actinium Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actinium main balance sheet or income statement drivers, such as Selling General Administrative of 15.7 M, Other Operating Expenses of 42.4 M or Total Operating Expenses of 55.5 M, as well as many exotic indicators such as Short Term Coverage Ratios of 16.4, Price To Sales Ratio of 143 or Dividend Yield of 0.0. Actinium financial statements analysis is a perfect complement when working with Actinium Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Actinium Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Actinium Pharmaceuticals Technical models . Check out the analysis of Actinium Pharmaceuticals Correlation against competitors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.

Actinium Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets137.9 M131.3 M42.9 M
Slightly volatile
Short and Long Term Debt Total3.1 MM860.7 K
Slightly volatile
Total Current Liabilities12.8 M12.2 M6.3 M
Slightly volatile
Accounts Payable12.2 M11.6 M4.5 M
Slightly volatile
Cash131.5 M125.2 M40.8 M
Slightly volatile
Cash And Short Term Investments131.5 M125.2 M40.8 M
Slightly volatile
Common Stock Total Equity24 K25.3 K65 K
Slightly volatile
Common Stock Shares Outstanding29.2 M27.8 M8.6 M
Slightly volatile
Liabilities And Stockholders Equity137.9 M131.3 M42.9 M
Slightly volatile
Other Stockholder Equity428.9 M408.5 M197.1 M
Slightly volatile
Total Liabilities57.6 M54.9 M14.6 M
Slightly volatile
Total Current Assets134 M127.6 M41.8 M
Slightly volatile
Common Stock22.2 K23.4 K65 K
Slightly volatile
Property Plant And Equipment Net3.6 M3.4 M882.1 K
Slightly volatile
Non Current Assets Total3.9 M3.7 M1.1 M
Slightly volatile
Other Current Assets2.5 M2.3 M1.1 M
Slightly volatile
Property Plant And Equipment Gross4.1 MM965.5 K
Slightly volatile
Short Term Debt339.1 K572.7 K305.5 K
Slightly volatile
Property Plant Equipment3.6 M3.4 M882.1 K
Slightly volatile
Capital Surpluse201.8 M378.7 M183.7 M
Slightly volatile
Other Assets450.8 K347.3 K277 K
Slightly volatile
Short Term Investments29.8 K40.2 K27.1 K
Slightly volatile
Long Term Investments39.9 K44.9 K48.9 K
Slightly volatile
Net Invested Capital42.2 M76.5 M29.6 M
Slightly volatile
Net Working Capital121.1 M115.4 M39.2 M
Slightly volatile
Long Term Debt Total90.4 K173.6 K65.9 K
Slightly volatile
Capital Lease Obligations3.1 MM725.4 K
Slightly volatile
Capital Stock22.2 K23.4 K87.8 K
Slightly volatile
Non Current Liabilities Other2.6 K2.7 K476.4 K
Slightly volatile
Other Liabilities28 M31.5 M34.3 M
Slightly volatile

Actinium Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative15.7 M15 M7.9 M
Slightly volatile
Other Operating Expenses42.4 M40.4 M21.9 M
Slightly volatile
Total Operating Expenses55.5 M52.9 M23.6 M
Slightly volatile
Depreciation And Amortization844 K803.9 K267.8 K
Slightly volatile
Research Development39.8 M37.9 M16.2 M
Slightly volatile
Interest Income2.9 M2.7 M2.2 M
Slightly volatile
Reconciled Depreciation463.4 K752 K253.6 K
Slightly volatile

Actinium Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow87.5 M83.3 M35.2 M
Slightly volatile
Begin Period Cash Flow118.1 M112.5 M32.3 M
Slightly volatile
Stock Based Compensation2.4 M3.9 M2.9 M
Very volatile
Depreciation789.6 K752 K260.7 K
Slightly volatile
Change To Account Receivables187.2 K210.6 K229.3 K
Slightly volatile
Sale Purchase Of Stock33.4 M31.8 M17.8 M
Slightly volatile
Change To Netincome1.9 M2.5 MM
Pretty Stable
Issuance Of Capital Stock24.8 M18.3 M23.1 M
Slightly volatile
Dividends Paid9089001.2 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio143225128
Slightly volatile
Dividend Yield0.00.00.0
Slightly volatile
Days Of Payables Outstanding11.1 K6.1 K12.5 K
Slightly volatile
Payables Turnover0.0590.06210.0653
Slightly volatile
Cash Per Share4.935.1915.8326
Slightly volatile
Quick Ratio9.689.224.9639
Slightly volatile
Net Income Per E B T1.091.111.0048
Slightly volatile
Cash Ratio9.689.224.9638
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.10.95771.0136
Slightly volatile
Current Ratio9.869.395.1106
Slightly volatile
Fixed Asset Turnover0.380.41.5075
Slightly volatile
Debt Ratio0.02470.0262.1002
Slightly volatile
Price Sales Ratio143225128
Slightly volatile
Asset Turnover0.01280.01040.0135
Slightly volatile
Gross Profit Margin0.470.370.511
Slightly volatile

Actinium Fundamental Market Drivers

Forward Price Earnings6.8399
Cash And Short Term Investments108.9 M

Actinium Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Actinium Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Actinium Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Actinium Pharmaceuticals investors use historical funamental indicators, such as Actinium Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Actinium Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Actinium Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Actinium Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Actinium Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Actinium Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue40.2 M42.3 M
Cost Of Revenue803.9 K844 K
Total RevenueM0.0
Ebit Per Revenue(38.08)(39.98)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Actinium Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Actinium Pharmaceuticals' short interest history, or implied volatility extrapolated from Actinium Pharmaceuticals options trading.

Pair Trading with Actinium Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actinium Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Actinium Stock

  0.85EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Actinium Stock

  0.82TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.78KA Kineta Inc Report 29th of March 2024 PairCorr
  0.72MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.71VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.68DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Actinium Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Actinium Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Actinium Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Actinium Pharmaceuticals to buy it.
The correlation of Actinium Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Actinium Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Actinium Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Actinium Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
Check out the analysis of Actinium Pharmaceuticals Correlation against competitors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Actinium Stock analysis

When running Actinium Pharmaceuticals' price analysis, check to measure Actinium Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinium Pharmaceuticals is operating at the current time. Most of Actinium Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Actinium Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinium Pharmaceuticals' price. Additionally, you may evaluate how the addition of Actinium Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Is Actinium Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.93)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.32)
Return On Equity
(0.87)
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.